OnKure Therapeutics (OKUR) Operating Expenses (2020 - 2026)

OnKure Therapeutics (OKUR) has reported Operating Expenses for 7 consecutive years, with $16.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Expenses rose 3.52% year-over-year to $16.9 million; the trailing twelve-month figure through Jun 2026 stood at $62.1 million (down 2.2% YoY), and the FY2025 full-year result was $63.0 million, up 15.75% from the prior year.
• Operating Expenses rose to $16.9 million in Q2 2026 per OKUR's latest filing, from $15.6 million in the prior quarter.
• Across five years, Operating Expenses topped out at $21.0 million in Q2 2023 and bottomed at -$21.1 million in Q4 2023.
• Historically, Operating Expenses has averaged $13.4 million across 5 years, with a median of $15.0 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Operating Expenses slumped 244.99% in 2023, then jumped 188.57% in 2024.
• Over 5 years, Operating Expenses stood at $14.6 million in 2022, then plunged by 244.99% to -$21.1 million in 2023, then surged by 188.57% to $18.7 million in 2024, then slipped by 24.46% to $14.1 million in 2025, then climbed by 19.64% to $16.9 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $16.9 million, $15.6 million, and $14.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.